B-CLEAN STUDY RESULTS

<u>Alan N. Barkun¹</u>, Myriam Martel¹, Ian L. Epstein², Pierre Hallé³, Robert J. Hilsden⁴, Paul D. James⁵, Alaa Rostom⁶, Michael Sey⁷, Harminder Singh⁸, Richard Sultanian⁹, Jennifer J. Telford¹⁰, Daniel Von Renteln¹¹, Kristina Candido¹

¹ Mcgill University Health Center, McGill University, Montreal, QC; ² Dalhousie University, Halifax, NS; ³
 Hôpital Du Saint-sacrement, Québec, QC; ⁴ University Of Calgary, Calgary, AB; ⁵ University Health Network, Toronto, ON; ⁶ University Of Ottawa, Ottawa, ON; ⁷ Western University, London, ON;
 ⁸ University Of Manitoba, Winnipeg, MB, ⁹ Division Of Gastroenterology, University Of Alberta, Edmonton, AB; ¹⁰ University Of British Columbia, Vancouver, BC; ¹¹ University Of Montreal, Montreal, QC, Canada

Conflict of Interest Disclosure

(over the past 24 months)

Commercial or Non- Profit Interest	Relationship
Cook Medical	advisory board, consultant
Olympus	advisory board, consultant
Pendopharm	advisory board, consultant, research support
ATGEN	advisory board, research support

INTRODUCTION

- Key quality indicators of colonoscopy, cecal intubation rate and polyp/adenoma detection rates, are associated with the quality of bowel cleansing
- An inadequate level of bowel cleansing also results in further costs (1% - 1%)
- The discomfort and inconvenience of bowel preparation may affect the acceptability and uptake of colonoscopy in screening programs

Superiority of split-dose preprations

Study	Experin Events		Co Events	ontrol Total		OR	95%-CI	W(random)
Vanner et al. 1990	18	54	38	48		0.13	[0.05; 0.32]	2.6%
Paoluzi et al. 1993	51	80	45	80	- •	1.37	[0.73; 2.58]	3.0%
Kolts et al. 1993	27	34	37	79		4.38	[1.71; 11.22]	2.6%
Marshall et al. 1993	60	70	66	73		0.64	[0.23; 1.78]	2.4%
Cohen et al 1994	90	143	141	279		1.66	[1.10; 2.51]	3.3%
Chia et al. 1995	33	39	25	40		3.30	[1.12; 9.72]	2.3%
Unal et al. 1998	15	18	12	28		6.67	[1.57; 28.36]	1.8%
Habr-Gama et al 1999	34	40	33	40		1.20	[0.37; 3.95]	2.2%
Arezzo et al. 2000	68	100	88	200		2.70	[1.63; 4.48]	3.2%
Young et al. 2000	131	169	86	154		2.73	[1.68; 4.41]	3.2%
El sayed et al. 2003	75	91	66	96	- 10 -	2.13	[1.07; 4.25]	2.9%
Tasci et al 2003	510	517	380	436		10.74	[4.84; 23.82]	2.8%
Ell et al 2003	76	123	15	62		5.07	[2.55; 10.06]	3.0%
Aoun et al. 2005	52	68	41	73		2.54	[1.23; 5.24]	2.9%
Hwang et al 2005	30	40	33	40		0.64	[0.22; 1.88]	2.3%
Parra-Blanco et al. 2006	36	45	49	132		6.78	[3.01; 15.25]	2.8%
Wruble et al. 2007	144	171	50	68		1.92	[0.98; 3.78]	3.0%
Johanson et al 2007	184	207	169	208		1.85	[1.06; 3.22]	3.1%
Abdul-Baki et al. 2008 I	177	199	78	183		10.83	[6.37; 18.42]	3.2%
Worthington et al. 2008	27	32	24	33		2.02	[0.60; 6.88]	2.1%
Malik et al. 2009	74	80	31	41		3.98	[1.33; 11.90]	2.3%
Chen TA et al 2009	103	140	35	136		8.03	[4.69; 13.75]	3.2%
Corporaal et al. 2010	209	220	77	87		2.47	[1.01; 6.04]	2.6%
Cohen et al. 2010	48	55	49	55		0.84	[0.26; 2.68]	2.2%
Park SS et al. 2010	61	95	95	190		1.79	[1.08; 2.98]	3.2%
Marmo et al. 2010	327	448	186	447	-+-	3.79	[2.86; 5.02]	3.5%
Matro et al 2010	51	60	56	65		0.91	[0.34; 2.47]	2.5%
Rex et al 2010	62	68	60	68		1.38	[0.45; 4.21]	2.3%
Samarasena et al. 2012	83	105	30	117		10.94	[5.84; 20.48]	3.0%
Manno et al. 2012	160	168	156	168		1.54	[0.61; 3.87]	2.6%
Flemming et al. 2012	107	127	74	123		3.54	[1.95; 6.45]	3.1%
Rex et al. 2013	256	305	221	298		1.82	[1.22: 2.72]	3.3%
Seo et al. 2013	75	102	72	103		1.20	[0.65; 2.20]	3.1%
Voiosu et al. 2013	63	94	49	87		1.58	[0.86; 2.88]	3.1%
Cesaro et al. 2013	24	51	67	102		0.46	0.23, 0.92	3.0%
De Leone et al. 2013	72	79	70	78	-	1.39	[0.46; 4.21]	2.3%
Random effects mod		4437	0.5605	4517	\$	2.23	[1.68; 2.95]	100%
Heterogeneity: I-squared=83	tau-so	juared=	•0.5085, p<	0.0001				
					0.1 0.5 2 10			
					Odds Ratio			

Recommended colonoscopy regimen

- Use of a split-dose bowel cleansing regimen is strongly recommended for elective colonoscopy (Strong recommendation, high-quality evidence)
- A same-day regimen is an acceptable alternative to split dosing, especially if afternoon exam (Strong recommendation, high-quality evidence)

The 2nd dose of split preparation should start 4–6 hours before the colonoscopy (end 2hrs pre; no longer than 4 hours pre [ESGE]) (Strong recommendation, moderate-quality evidence)

Split-dose preparations and polyp detection

- N=28, n=8,842
- Split-dose vs day-before (N=7):
 - increased ADR (1.26, 1.10–1.44)
 - Greater advanced adenoma detection (1.53, 1.22– 1.92)
 - Higher SSP detection (2.48, 1.21–5.09).

Split-dose vs same-day (N=8), no differences
 For various split-dose vs split-dose trials (N=14) no superior split-dosing regimen was identified

SAME DAY VS SPLIT DOSING

- N=10, n=1807; 3 used Pico, 6 3-day low residue
- Adequate cleansing: Same 85.3% vs Split 86.3% (P=NS)
- Compliance: 89.7% vs 96.6% (P=0.03)
- Sleep disturbance: 13.7% more in Split (P=NS)
- Nausea: 10.5% more in Same group (P=0.01)
- Pico Same cleaned better than Pico Split (not Randomized)
- PEG vs Pico in various regimens: no difference in cleansing, more compliance with Pico

Bucci, Gastro Revs Pract, 2019

PEG vs Pico Sulfate preps

- N=15: Pico resulted in cleaner, better compliance, better tolerated preparations
- But very few split-dosing, limited methodology in 12 studies (concealment of randomization*)
- N=25 RCTs: trend to better preps with PEG (RR 0.93; 0.86-1.01, P = 0.07)
- More likely to complete SPMC (1.08; 1.04-1.13) and willing to repeat (1.44; 1.25-1.67)
- Lower adverse events SPMC (0.78; 0.66-0.93)
- No differences in PDR or ADR

Cheng, Surg Endosc, 2016; Jin, Eur J Clin Pharmacol, 2016

PEG vs Sodium Picosulfate with Magnesium Citrate

- N=13, good quality, large heterogeneity
- SPMC slightly better cleansing than PEG (RR 1.06; 1.02-1.11)
- SPMC better tolerated than PEG
- No differences in effectiveness or tolerability between SPMC and NaP
- Side effects similar, except for dizziness (1.71; 1.32 to 2.21) in favour of PEG, and vomiting (0.35; 0.13 to 0.95) in favour of single-dose SPMC vs. split-dose
- Problem: many studies used single dose PEG

Van Lieshut, UEGJ, 2017

Low residue vs Clear Liquid Diet

- N=9, n=1686 patients (5 w split preps)
- No differences in adequate bowel preparation rates (OR 1.21; 0.64-2.28)
- Greater tolerability with LRD (OR 1.92; 1.36-2.70)
- Greater willingness to repeat with LRD (OR 1.86; 1.34-2.59)
- No differences in adverse effect rates (OR 0.88; 0.58-1.35)
- ?NPO x 2hrs with split-dosing...

NPO duration prior to colonoscopy

Prep within 8 hours of colonoscopy

- N=28 RCTs, 2 controlled, 10 observational studies
- N=6 (n=2,421) reported on aspiration; none found that shorter NPO status prior to colonoscopy increased aspiration risk (but studies not designed to assess this)

Use of enhanced instructions

N=8 RCTs, n=3795

- Better prep quality with enhanced instructions (OR=2.35, 1.65-3.35)
- Results independent of different purgative types, administration methods, or diet restriction
- Also greater willingness to repeat the preparation (1.91; 1.20-3.04)

Visual aid, Social Media, SMS, telephone, Tel ap, additional explanations, cartoon visual aids, redesigned booklets – written/verbal instructions of both

Guo, GIE, 2017

Use of a smart phone app

- N=6, n=1665,
- Greater adequate prep: 87.5% vs 77.5% (OR=2.67, P=0.05)
- Only a trend if only looking at RCTs (OR 2.66, P=0.07)
- When only using BBPS, mean diff=0.9 (P<0.01)</p>

Desai, Endo Int, 2019

Predictors of poor bowel preparation

Table 1. Summary of pati	ent-related factors to poor bowel preparation
Patient characteristics	
Age	• Higher risk of inadequate bowel preparation in patients 65 or older
	 Patients seem to tolerate well the bowel preparation intake
	Higher rate on non-compliance
	 30-min walk during preparation intake may increase motility
	 No optimal bowel preparation was found
Gender	 Male patients had higher risk of inadequate bowel cleanliness compared to females
Socio-economic status	 Patients with Medicare programs, low education status and low income are at higher risk of inadequate bowel preparation
	Higher rate of non-compliance
Other	 American Society of Anesthesiology was not found to be associated to inadequate bowel preparation in the general population
Co-morbidities	
Inflammatory bowel disease	 Patients with repeated colonoscopy with required excellent quality of cleanliness to evaluate the mucosa
	Higher level of anxiety
	 No preparation was found to be better, but sodium phosphate should be avoided due to potential superficial mucosal abnormalities and in rare cases nephrotoxicity
In-patients	 Hospitalized patients have higher risk of poor bowel preparation compared to outpatients
	 Higher prevalence of comorbidities such as hypertension, diabetes, and chronic kidney disease and ischemic heart disease
	 Indications where less for screening and constipation but more often for anemia and positive occult blood testing
	 No optimal bowel preparation was found
	 Positive impact of ward nurse education on patient compliance and bowel cleanliness
Body mass index (BMI)	 Higher BMI was found in some study to be associated with poor bowel cleanliness but not in all studies
Diabetes mellitus	 Patients with slower gastric emptying and higher risk of constipation
	Higher rate of inadequate bowel cleanliness
	• RCT did not demonstrate 6-L PEG to be more
	 Addition of 10 mg magnesium citrate was more efficient than without (combined with 4-L PEG) and another RCT suggested multimodal strategy including an educational intervention, a low-fiber diet for 3 days followed by a 24-h liquid diet before the colonoscopy with accompanied adjustments of glucose-lowering agents
Cirrhosis	Higher inadequate bowel cleanliness in cirrhosis patients
	Water-salt imbalance in liver disease patients affects intestinal fluid permeability during standard colonic preparation and may be responsible for a suboptimal bowel cleanliness
Constipation	Higher inadequate bowel cleanliness in constipated patients
	Patients with slower colonic transit time
	 No optimal bowel preparation was found but probiotic treatment for 2 weeks prior to colonoscopy was found to be effective in one trial
Neurological condition	Higher inadequate bowel cleanliness in patients with Parkinson or dementia/stoke

Iartel, Curr Treat Opt Gastro, 2019

Predictors of poor bowel preparation

N=24, n=49,868; world region variations; significant predictors (*if split-dosing):

- Age (OR: 1.20)
- Male sex (OR: 0.85); Race* (OR: 0.93)
- Inpatient status (OR: 0.57)
- Diabetes mellitus (OR: 0.58)
- Hypertension (OR: 0.58)
- Cirrhosis (OR: 0.49)
- Narcotic use (OR: 0.59)
- Constipation (OR: 0.61)
- Stroke (OR; 0.51)*
- TCA use (0.51)*

Current status of bowel preps

- Split-dosing superior
- Yet limited data on using split-dose vs day before
- Many still use day before for AM patients
- Limited data on same-day vs split-dosing
- Limited data on 2L vs 4L split-dose PEG
- Limited RCT data from Canada on PEG preparations

THE BCLEAN INITIATIVE

10 participating Canadian Centres



BCLEAN studies at DDW

Sa 1748 – Day before vs split-dose preps
 Mo 1068 - Same-day preps
 Mo 1662 - Hi vs Lo split-dose PEG preps
 Dr. H Singh: Sa 1754 - Sleep disturbances and travel interruption

The <u>Bowel CLE</u>Ansing: a <u>National</u> initiative (B-CLEAN)

- Multicenter blinded* randomized study across Canada
- Main outcome: bowel cleanliness
- Objectives: To address issue of
 - Timing of colonoscopy : morning vs. afternoon
 - High vs. low volume
 - Timing of preparation, incl. same day
 - Influence of diet (clear liq. vs. no residue)

Timing of endoscopy

Early colonoscopy: 7:30 AM to 10h30 AM

Later colonoscopy: 10:30 AM to 4:30 PM

Bowel preparation regimens

High volume PEG split-dose

- Colyte® or PegLyte®
- 1st dose: 2L starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes.
- 2nd dose: 2L of preparation the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes.

Bowel preparation regimens

Low volume PEG split-dose

- Bi-PegLyte®
- 15mg Bisacodyl at 2:00 PM the day before the procedure. (use of antacids is not permitted within one hour)
- 1st dose: after the first bowel movement (or within 6 hours of taking the Bisacodyl), 1L at a rate of 240 mL every 10 minutes.
- 2nd dose: 1L of preparation the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes.

Bowel preparation regimens

High volume PEG non split, day before

- Colyte® or PegLyte®
- 4L starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.

Low volume PEG non split, same day

- Bi-PegLyte®
- 15mg Bisacodyl at 2:00 PM the day before the procedure. (use of antacids is not permitted within one hour)
- 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes.

Clear Liquid Diet

<u>Starting the morning before the colonoscopy</u> (no normal breakfast)

ALLOWED: Clear Liquid Diet	NOT ALLOWED:
 Example: Clear soup, broth or bouillon Sports drinks (Gatorade) or soft drinks (7- Up, Ginger Ale, etc.) Clear fruit juices such as apple juice, white grape or white cranberry juice Kool-Aid, Jello (not red, purple, blue or green) Tea, coffee (without milk or cream) Popsicles (not red, purple, blue or green) Water 	 NO RED, PURPLE, BLUE or GREEN colored liquids Orange, pineapple or red grape juice Milk or dairy products Milk shakes Malt Alcoholic drinks Dark colored soft drinks such as Coke or Pepsi NO liquids containing PULP

Low residue diet

<u>Starting the morning, the day before your colonoscopy</u> (no normal breakfast) until bedtime

ALLOWED

Example:

- Well-cooked, tender meat and fish
- Limited servings of steamed well-cooked vegetables that do not include skins
- Canned fruit, grapes without skins, honeydew melon, peaches without skins, watermelon
- White bread, buns, melba toast,
- White rice or refined pasta and noodles
- Tofu, smooth nut butters, eggs

Consume a lot of clear fluids, including:

- Clear soup, broth or bouillon
- Sports drinks (Gatorade) or soft drinks (7- Up, Ginger Ale, etc.)
- Clear fruit juices such as apple juice, white grape or white cranberry juice
- Kool-Aid, Jello (not red, purple, blue or green)
- Tea, coffee (without milk or cream)
- Popsicles (not red, purple, blue or green)
- Water

Low residue diet cont

NOT ALLOWED


- Salami, sausages, cold cuts
- Any raw vegetables, corn, tomato seeds, vegetables from the cruciferous family such as broccoli, cauliflower, brussels sprouts, cabbage, kale, swiss chard, etc (even if cooked)
- All other fruit
- Whole grain, sesame seeds, flax
- Whole wheat (brown), quinoa, wild rice, multigrain
- Beans, lentils, peas, chunky nut butters
- Dairy products

NO RED, PURPLE, BLUE or GREEN colored liquids

- Orange, pineapple or red grape juice
- Milk or dairy products; Milk shakes
- Malt
- Alcoholic drinks
- Dark colored soft drinks such as Coke or Pepsi

NO liquids containing PULP

Starting the morning, the day before the colonoscopy: clear liquid <u>diet</u>



* See complete description in section 4.2

Note 1: Patients per group to detect a non inferiority of 10% (power of 0.80), alpha=0.05. One sided test **Note 2:** All proportions were calculated considering a 15% drop-off

Note 3: Poor evidence for all comparisons resulting in a limitation for sample size precision

* With a Power of 80%, a true difference will be missed 20% the time

Primary objective and endpoint

The primary objective of this clinical study was to determine <u>the cleansing efficacy of different bowel preparations</u> for outpatients while varying

- assigned diet,
- method of administration and
- volume of the PEG solution

stratified according to time of scheduled colonoscopy (10:30 AM vs later)

■ The primary endpoint was to evaluate the bowel cleansing score rate for a total of BBPS score ≥6 and/or all BBPS <u>score ≥6</u> <u>and/or each segment ≥2</u> as rated by the blinded endoscopist

The second primary endpoint was the bowel cleansing score rated by the blinded endoscopist using the <u>Boston Bowel</u> <u>Preparation Scale (BBPS)</u> dichotomized using a <u>cut-off of 7 or</u> <u>greater</u>

Secondary endpoints (I)

- Subject willingness to repeat the preparation (%)
- Withdrawal time and total procedural time (mn)
- Cecal or ileal intubation rate for colonoscopies (%)
- Polyp detection and polypectomy rate (%)
- Right colon polyp detection rate (%)
- Specific lesional rates identified according to pathology (adenoma, hyperplastic, sessile serrated polyp, advanced neoplasia, cancer) (%)

Secondary endpoints (II)

- Subject product completion (% of total required intake and time to complete mn)
- Subject travel time to endoscopy unit (hrs) and any incontinence (%)
- Assess other potential predictors of
 - clean preparation or
 - willingness to repeat


- These include
 - age
 - gender
 - comorbidities
 - indication
 - social economic status
 - use of a patient support tool
 - endoscopist profile
 - concomitant medications
 - time between end of last dose and endoscopy
 - previous failed colonoscopy due to preparation and
 - constipation

Secondary endpoints (III)

 Montreal score compared to Boston Bowel Preparation Score
 Ottawa Bowel Preparation Scores

BOSTON:


Score 3 segments after cleaning: Right + Transverse (include both flexures) + Left Score pour 3 segments après nettoyage: Droit + Transverse (inclus les deux angles) + Gauche



Write NA if segment surgically removed Inscrire mention NA si segment chirurgicalement manquant

	BBPS score
Visual description/ Description visuelle	
Entire mucosa of colon segment seen well with no residual staining, small fragments of stool, or opaque liquid/ Muqueuse du segment de colon parfaitement bien vue, sans aucun résidus de selles ou de liquide teinté	3
Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well/ Résidus minimes de selles et/ou de liquide teinté, mais la muqueuse du segment de colon est globalement bien vue	2
Portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen because of staining, residual stool, and/or opaque liquid/ Des portions de muqueuse du segment de colon sont vues tandis que d'autres ne sont pas vues à cause de matières solides et/ou de liquide teinté	1
Unprepared colon segment with mucosa not seen because of solid stool that cannot be cleared/ Segment de colon non préparé avec muqueuse non visualisée à cause de matières solides qui ne peuvent pas être aspirées	0

BOSTON BOWEL PREP SCORE



Score possible de 0-9

Lai, GIE, 2009

Inclusion Criteria

Outpatients

- 18 years or older
- Able to comprehend the trial
- Have an indication for full colonoscopy


Exclusion Criteria

General exclusion criteria:

- Subject refusal
- Previous bowel preparation in the last 14 days
- Pregnancy or breastfeeding
- Reduced mobility
- Known allergy to preparation constituent

Medical/Endoscopic exclusion criteria:

- Suspected or diagnosed with bowel obstruction
- Any colonic surgery
- Toxic megacolon
- Ileus
- Ischemic colitis
- Decompensated heart failure
- Severe acute renal failure
- Severe electrolyte imbalance



Results – Patient demographics

	All patients N=3473
Age	56.3 ± 13.3
Female	53.2%
BMI	27.8 ± 14.4
Help required for preparation directive	1.0%
Known IBD	7.3%
Received colonoscopy in the past	58.1%
Previous failed colonoscopy	4.0%
Narcotic use in the last 24 hours	3.3%
Chronic laxative use or known medication induced constipation	9.5%
Functional constipation*	9.8%
Indication	
Non screening	37.8%
Screening	37.4%
Surveillance	24.8%

Results comparisons

#1 Split-dose high-volume PEG compared to splitdose low-volume PEG with Bisacodyl

#2 Same-day low-volume PEG versus split-dose high-volume PEG versus split-dose low-volume PEG with Bisacodyl (PM patients only)

 #3 Day before high-volume PEG versus split-dose high-volume and/or split-dose low-volume PEG with Bisacodyl (for AM patients only)

#1 Split-dose high-volume PEG compared to split-dose low-volume PEG with Bisacodyl

	Split-dose	Split-dose	
	High-volume	Low-volume	
	N=1157	N=1157	
	AM+PM	AM+PM	
Withdrawal time	8.3 ± 3.2	8.4 ± 3.5	0.742
Total Boston preparation score	7.4 ± 1.7	7.0 ± 1.9	0.003
BBPS Adequate*	90.8%	88.1%	0.041
Patient willing to repeat the	66.9%	91.9%	<u><0.001</u>
preparation			
Patient Tolerance (1-10 scale)	7.2 ± 2.3	8.1 ± 1.9	<u><0.001</u>
Caecal intubation	97.4%	95.6%	0.023
Polyp detection rate	49.0%	45.8%	0.137
Functional constipation**	9.4%	10.4%	0.422

* Boston Bowel Preparation Scale (BBPS) dichotomized using a cut-off of ≥6 and/or all segment ≥2 scores

** According to the ROME III classification

NB: incontinence was evaluated in a sub-study by Dr Singh et al.,

#2 Same-day low-volume PEG versus split-dose highvolume PEG versus split-dose low-volume PEG with Bisacodyl – - (for PM patients only) -

	Same-day Iow-volume N=583 PM	Split-dose high-volume N=582 PM		Split-dose low-volume N=585 PM		Same-day low-volume vs Split- dose high or low volume N=1167 PM	
Withdrawal time	8.4 ± 4.1	8.2 ± 3.3	0.591	8.3 ± 3.2	0.609	8.2 ± 3.3	0.528
Total BBPS	7.5 ± 1.7	7.4 ± 1.6	0.523	7.1 ± 1.8	<0.001	7.3 ± 1.73	0.012
BBPS Adequate*	90.5%	92.2%	0.338	87.9%	0.173	90.1%	0.764
Patient willing to repeat the preparation	91.0%	68.9%	<0.001	92.5%	0.395	81.2%	<0.001
Patient Tolerance (1-10 scale)	8.1 ± 1.9	7.2 ± 2.3	<0.001	8.2 ± 1.9	0.652	7.7 ± 2.1	0.001
Caecal intubation	97.0%	97.6%	0.549	87.9%	0.232	96.6%	0.673
Polyp detection rate	47.0%	47.7%	0.823	48.4%	0.656	48.1%	0.699

* Boston Bowel Preparation Scale (BBPS) dichotomized using a cut-off of ≥6 and/or all segment ≥2 scores NB: incontinence was evaluated in a sub-study by Dr Singh et al.,

#3 Day before high-volume PEG versus split-dose highvolume PEG and/or split-dose low-volume PEG with Bisacodyl - (for AM patients only) -

	Day before high-volume N=579	Split-dose high-volume N=575		Split-dose low-volume N=572		(High or Low) split-dose N=1147	
Withdrawal time	8.8 ± 3.8	8.4 ± 3.1	0.203	8.4 ± 3.2	0.203	8.5 ± 3.4	0.208
Total BBPS	6.2 ± 2.0	7.3 ± 1.7	<u><0.001</u>	7.2 ± 1.8	<u><0.001</u>	7.2 ± 1.8	<u><0.001</u>
BBPS Adequate*	71.8%	89.4%	<u><0.001</u>	88.2%	<u><0.001</u>	88.8%	<u><0.001</u>
Boston ≥ 7	42.9%	65.5%	<u><0.001</u>	66.2%	<u><0.001</u>	63.8%	<u><0.001</u>
Patient willing to repeat the preparation	59.6%	64.8%	0.107	91.2%	<u><0.001</u>	78.5%	<u><0.001</u>
Patient Tolerance (1-10 scale)	7.0 ± 2.3	7.2 ± 2.4	0.106	8.0 ± 1.8	<u><0.001</u>	7.6 ± 2.1	<u><0.001</u>
Caecal intubation	94.4%	97.2%	<u>0.023</u>	95.6%	0.394	96.4%	0.068
Polyp detection rate	43.5%	50.3%	<u>0.026</u>	43.1%	0.909	46.7%	0.222

* Boston Bowel Preparation Scale (BBPS) dichotomized using a cut-off of ≥6 and/or all segment ≥2 scores NB: incontinence was evaluated in a sub-study by Dr Singh et al.,

Conclusion 1

Split-dose <u>high-volume</u> PEG (2L+2L) compared to split-dose <u>low-volume</u> PEG (1L+1L) with bisacodyl (15mg)

 Split-dose high-volume PEG - Independent of time of procedure (AM or PM) or diet (clear liquid or low residue diet)

- Improved bowel cleansing according to the BBPS
- Improved cecal intubation
- Improved polypectomy rates

However,

- Lower patient willingness to repeat the bowel preparation
- Lower patient tolerance

Conclusion 2

Same-day low-volume PEG (2L) compared split-dose high-volume PEG (2L+2L) and/or split-dose low-volume (1L+1L) PEG with bisacodyl (15mg)

Low volume PEG given the day of the colonoscopy independent of diet (clear liquid or low residue)

Similar bowel cleanliness compared to split-dose high-volume PEG

"Better bowel cleanliness" compared to split-dose low volume PEG

Same-day low-volume PEG

Greater willingness-to-repeat compared to split-dose high-volume PEG

No different willingness-to-repeat compared to split-dose low-volume PEG

Conclusion 3

Day before high-volume PEG (4L) versus split-dose high-volume PEG (2L+2L) and/or split-dose low-volume PEG (1L+1L) with Bisacodyl (15mg)

- Day before high-volume PEG independent of diet (clear liquid or low residue)
 - Worse bowel cleanliness compared to split-dose high volume PEG
 - Worse bowel cleanliness compared to split-dose low volume PEG
 - Lower patient willingness to repeat compared to the split-dose low-volume PEG
 - Not significantly different patient willingness to repeat compared to the split-dose high-volume PEG
 - Inferior cecal intubation and polyp detection vs split-dose high-volume PEG

DAY BEFORE PREPARATIONS ARE OUT

Acknowledgments

Myriam Martel,

- Ian L. Epstei, Pierre Hallé, Robert J. Hilsden, Paul D. James, Alaa Rostom, Michael Sey, Harminder Singh, Richard Sultanian, Jennifer J. Telford, Daniel Von Renteln,
- Kristina Candido, Meaghan Smith
- Pendopharm Inc. at arms length funding of this investigator-initiated trial